Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types

被引:43
作者
Wang, Chiyun [1 ,2 ]
Hahn, Elan [1 ,2 ]
Slodkowska, Elzbieta [1 ,2 ]
Eskander, Antoine [3 ]
Enepekides, Danny [3 ]
Higgins, Kevin [3 ]
Vesprini, Danny [4 ]
Liu, Stanley K. [4 ]
Downes, Michelle R. [1 ,2 ]
Xu, Bin [1 ,2 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Otolaryngol Head & Neck Surg, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada
关键词
PD-L1 immunohistochemistry assay; Assay comparison; Head and neck carcinoma; Urothelial carcinoma; Prostatic carcinoma; CELL LUNG-CANCER; SQUAMOUS-CELL; EXPRESSION; IMMUNOTHERAPY; HEAD;
D O I
10.1016/j.humpath.2018.07.024
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Programmed death-ligand 1 (PD-L1) expression by tumor cells is a mechanism for down-regulation of antitumor T-cell responses and is a target for immunotherapy in various cancers. PD-L1 status as a predictor of treatment response has led to the development of multiple platforms with different reference cutoffs. We studied 128 cases of genitourinary and head/neck carcinomas, aiming to assess the frequency of PD-L1 positivity, interobserver reliability of PD-L1 interpretation, and the concordance of PD-L1 scoring between small samples from tissue microarray and whole sections using SP263 and SP142 clones. No prostatic carcinoma (0/21) was PD-L1 positive compared with 15% to 24% PD-L1 positivity in urothelial carcinoma (UC), hypo pharyngeal squamous cell carcinoma (HP-SCC), and high-grade salivary gland carcinoma. There was substantial interobserver agreement in determining overall PD-L1 positivity in UC and HP-SCC using SP263 (kappa = 0.702) and SP142 (kappa = 0.757) antibodies. Subgroup analysis for both antibodies showed excellent agreement in UC (kappa = 0.812 and 0.827) and moderate agreement in HP-SCC (kappa = 0.469 and 0.591). Moderate to substantial agreement between tissue microarray and whole sections was achieved using SP263 (overall, kappa = 0.573; UC, kappa = 0.424; and HP-SCC, kappa = 0.667) and SP142 (UC, kappa = 0.493). PD-L1 interpretation in genitourinary and head/neck carcinomas is reliable and reproducible among pathologists and across different tissue preparations. Tumor PD-L1 staining heterogeneity may lead to discrepant PD-L1 results between small biopsies and large sections from surgical resection in a subset of tumors (19% of UC and 15% of HP-SCC). Retesting in such cases may be required to determine patient suitability for anti PD-1/PD-L1 therapy. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 35 条
[11]   Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer [J].
Graff, Julie N. ;
Alumkal, Joshi J. ;
Drake, Charles G. ;
Thomas, George V. ;
Redmond, William L. ;
Farhad, Mohammad ;
Cetnar, Jeremy P. ;
Ey, Frederick S. ;
Bergan, Raymond C. ;
Slottke, Rachel ;
Beer, Tomasz M. .
ONCOTARGET, 2016, 7 (33) :52810-52817
[12]   PD-L1 expression in malignant salivary gland tumors [J].
Harada, Koji ;
Ferdous, Tarannum ;
Ueyama, Yoshiya .
BMC CANCER, 2018, 18
[13]   PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project [J].
Hirsch, Fred R. ;
McElhinny, Abigail ;
Stanforth, Dave ;
Ranger-Moore, James ;
Jansson, Malinka ;
Kulangara, Karina ;
Richardson, William ;
Towne, Penny ;
Hanks, Debra ;
Vennapusa, Bharathi ;
Mistry, Amita ;
Kalamegham, Rasika ;
Averbuch, Steve ;
Novotny, James ;
Rubin, Eric ;
Emancipator, Kenneth ;
McCaffery, Ian ;
Williams, J. Andrew ;
Walker, Jill ;
Longshore, John ;
Tsao, Ming Sound ;
Kerr, Keith M. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :208-222
[14]   PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma [J].
Hodgson, Anjelica ;
Slodkowska, Elzbieta ;
Jungbluth, Achim ;
Liu, Stanley K. ;
Vesprini, Danny ;
Enepekides, Danny ;
Higgins, Kevin ;
Katabi, Nora ;
Xu, Bin ;
Downes, Michelle R. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (08) :1059-1066
[15]   Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma [J].
Koshkin, Vadim S. ;
Grivas, Petros .
CURRENT ONCOLOGY REPORTS, 2018, 20 (06)
[16]   Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer [J].
Li, Chao ;
Huang, Cheng ;
Mok, Tony S. ;
Zhuang, Wu ;
Xu, Haipeng ;
Miao, Qian ;
Fan, Xirong ;
Zhu, Weifeng ;
Huang, Yunjian ;
Lin, Xiandong ;
Jiang, Kan ;
Hu, Dan ;
Chen, Xiaohui ;
Huang, Peisha ;
Lin, Gen .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) :1536-1543
[17]   Programmed Death Ligand-1 Expression Is Associated With Poor Disease Free Survival in Salivary Gland Carcinomas [J].
Mukaigawa, Takashi ;
Hayashi, Ryuichi ;
Hashimoto, Kazuki ;
Ugumori, Toru ;
Hato, Naohito ;
Fujii, Satoshi .
JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (01) :36-43
[18]   FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy [J].
Ning, Yang-Min ;
Suzman, Daniel ;
Maher, V. Ellen ;
Zhang, Lijun ;
Tang, Shenghui ;
Ricks, Tiffany ;
Palmby, Todd ;
Fu, Wentao ;
Liu, Qi ;
Goldberg, Kirsten B. ;
Kim, Geoffrey ;
Pazdur, Richard .
ONCOLOGIST, 2017, 22 (06) :743-748
[19]   HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy [J].
Notsuda, Hirotsugu ;
Bradbury, Penelope A. ;
Tsao, Ming-Sound .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) :422-424
[20]   Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians [J].
Outh-Gauer, Sophie ;
Alt, Marie ;
Le Tourneau, Christophe ;
Augustin, Jeremy ;
Broudin, Chloe ;
Gasne, Cassandre ;
Denize, Thomas ;
Mirghani, Haitham ;
Fabre, Elizabeth ;
Menard, Madeleine ;
Scotte, Florian ;
Tartour, Eric ;
Badoual, Cecile .
CANCER TREATMENT REVIEWS, 2018, 65 :54-64